Clinical trial GCT3013-05
A Randomized, Open-Label, Phase 3 Trial of Epocoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Genmab |
| EudraCT Identifier | 2020-003016-27 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04628494 |
| Inclusion criteria | Relapse or Refractory Diffuse Large B-cell Lymphoma CD20+ DLBCL, Failed previous HDT-ASCT or not eligible for HDT-ASCT.ECOG PS score 0-2Acceptable renal and liver functionPatient must have detectable disease by PET scan and by CT scan or MRI. |
| Last update |